[1] The low starter dose (0.25 mg) is specifically designed to minimise these effects
Because of how angiogenic it is, theres some very serious theoretical risk, especially for people with cancer, Dr McGuire says
Always consult your healthcare provider before discontinuing Wegovy
GLP-1s are serious medications with certain potential toxicities for some patients, including pancreatitis, thyroid cancer, and very rarely, but now officially acknowledged in the case of Wegovy blindness, caused by a condition called non-arteritic anterior ischemic optic neuropathy (NAION)
These pre-specified cardiometabolic measures help researchers understand the safety profile of the drug and make necessary adjustments to improve patient outcomes
Most of the evidence supporting this claim comes from a few observational studies